Literature DB >> 12095474

Irritable Bowel Syndrome.

Joel A. Sach1, Lin Chang.   

Abstract

Because treatment of irritable bowel syndrome (IBS) patients can be frustrating to the clinician and patient as well, the physician should strive to gain the patient's confidence with a concise, appropriate work-up and by offering reassurance and education that IBS is a functional disorder without significant long-term health risks. First-line treatment should be aimed at treating the most bothersome symptom. Tricyclic antidepressants are superior to placebo in reducing abdominal pain scores, as well as improving global symptom severity. Loperamide is superior to placebo in managing IBS-associated diarrhea. Whereas fiber has a role in treating constipation, its value for IBS or, specifically, in the relief of abdominal pain or diarrhea associated with IBS is controversial. Although certain antispasmodics have demonstrated superiority over placebo in managing abdominal pain, none of these agents are available in the United States. Probiotic therapy using Lactobacillus plantarum has demonstrated superiority to placebo in improving pain, regulating bowel habits, and decreasing flatulence. As studied in a recent placebo-controlled prospective study, Chinese herbal medicines significantly improved bowel symptom scores and global symptom profile, and reduced IBS-related quality of life impairment. Some of the most promising emerging therapies in IBS revolve around targeted pharmacotherapeutic modulation of serotonin receptors (ie, 5-HT3 and 5-HT4 subtypes), which are involved in sensory and motor functions of the gut. Other investigational agents that are also being explored include cholecystokinin antagonists, alpha2-adrenergic agonists (eg, clonidine), serotonin reuptake inhibitors (eg, citalopram), and neurokinin antagonists. IBS is best understood through the biopsychosocial paradigm, and therefore, its effective management requires a comprehensive multidisciplinary approach based on patient education and reassurance, enhanced by diet recommendations and lifestyle modifications, and complemented by pharmacotherapy and psychosocial intervention in more severe cases.

Entities:  

Year:  2002        PMID: 12095474     DOI: 10.1007/s11938-002-0049-3

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  48 in total

Review 1.  Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel.

Authors:  M D Gershon
Journal:  Aliment Pharmacol Ther       Date:  1999-05       Impact factor: 8.171

2.  A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome.

Authors:  K Niedzielin; H Kordecki; B Birkenfeld
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-10       Impact factor: 2.566

3.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Authors:  M Camilleri; A R Northcutt; S Kong; G E Dukes; D McSorley; A W Mangel
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

Review 4.  Antidepressants for functional gastrointestinal syndromes.

Authors:  R E Clouse
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

5.  Sleep disturbance influences gastrointestinal symptoms in women with irritable bowel syndrome.

Authors:  M Jarrett; M Heitkemper; K C Cain; R L Burr; V Hertig
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

6.  Carbohydrate malabsorption and the effect of dietary restriction on symptoms of irritable bowel syndrome and functional bowel complaints.

Authors:  R Goldstein; D Braverman; H Stankiewicz
Journal:  Isr Med Assoc J       Date:  2000-08       Impact factor: 0.892

Review 7.  Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.

Authors:  J Jailwala; T F Imperiale; K Kroenke
Journal:  Ann Intern Med       Date:  2000-07-18       Impact factor: 25.391

8.  Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study.

Authors:  I J Cook; E J Irvine; D Campbell; S Shannon; S N Reddy; S M Collins
Journal:  Gastroenterology       Date:  1990-01       Impact factor: 22.682

9.  Loperamide improves anal sphincter function and continence after restorative proctocolectomy.

Authors:  T Hallgren; S Fasth; D S Delbro; S Nordgren; T Oresland; L Hultén
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

10.  Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization.

Authors:  N J Talley; A R Zinsmeister; L J Melton
Journal:  Am J Epidemiol       Date:  1995-07-01       Impact factor: 4.897

View more
  3 in total

1.  Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes.

Authors:  Kyoung-Ah Kim; Jaegul Chung; Dong-Hae Jung; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2004-09-08       Impact factor: 2.953

2.  Paroxetine for somatic pain associated with physical illness: a review.

Authors:  Prakash S Masand; Meera Narasimhan; Ashwin A Patkar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

3.  Application of sequence-dependent electrophoresis fingerprinting in exploring biodiversity and population dynamics of human intestinal microbiota: what can be revealed?

Authors:  Geert Huys; Tom Vanhoutte; Peter Vandamme
Journal:  Interdiscip Perspect Infect Dis       Date:  2008-12-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.